367 related articles for article (PubMed ID: 21947696)
21. Neoadjuvant chemotherapy in squamous cell carcinoma of the esophagus using low dose continuous infusion 5-fluorouracil and cisplatin: results of a prospective study.
Aroori S; Parshad R; Kapoor A; Gupta SD; Kumar A; Chattophadyay TK
Indian J Cancer; 2004; 41(1):3-7. PubMed ID: 15105572
[TBL] [Abstract][Full Text] [Related]
22. HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma.
Learn PA; Yeh IT; McNutt M; Chisholm GB; Pollock BH; Rousseau DL; Sharkey FE; Cruz AB; Kahlenberg MS
Cancer; 2005 Jun; 103(11):2252-60. PubMed ID: 15834928
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer.
Shim HJ; Cho SH; Hwang JE; Bae WK; Song SY; Cho SB; Lee WS; Joo YE; Na KJ; Chung IJ
Am J Clin Oncol; 2010 Dec; 33(6):624-8. PubMed ID: 20142726
[TBL] [Abstract][Full Text] [Related]
24. Prognostic factors of metastatic or recurrent esophageal squamous cell carcinoma in patients receiving three-drug combination chemotherapy.
Chen WW; Lin CC; Huang TC; Cheng AL; Yeh KH; Hsu CH
Anticancer Res; 2013 Sep; 33(9):4123-8. PubMed ID: 24023359
[TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF NAC) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysis.
Yamashita K; Katada N; Moriya H; Hosoda K; Mieno H; Katada C; Koizumi W; Hoshi K; Watanabe M
Gen Thorac Cardiovasc Surg; 2016 Apr; 64(4):209-15. PubMed ID: 26868531
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer.
Shiga H; Heath EI; Rasmussen AA; Trock B; Johnston PG; Forastiere AA; Langmacher M; Baylor A; Lee M; Cullen KJ
Clin Cancer Res; 1999 Dec; 5(12):4097-104. PubMed ID: 10632346
[TBL] [Abstract][Full Text] [Related]
27. Polymorphism in epidermal growth factor receptor intron 1 predicts prognosis of patients with esophageal cancer after chemoradiation and surgery.
Lee JM; Yang SY; Yang PW; Shun CT; Wu MT; Hsu CH; Lin CC; Cheng JC; Wang YH; Chuang TH; Chen JS; Hsu HH; Huang PM; Kuo SW; Lee YC
Ann Surg Oncol; 2011 Jul; 18(7):2066-73. PubMed ID: 21298351
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant chemotherapy with 5-fluorouracil and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma.
Lee J; Lee KE; Im YH; Kang WK; Park K; Kim K; Shim YM
Ann Thorac Surg; 2005 Oct; 80(4):1170-5. PubMed ID: 16181835
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus.
Ojima T; Nakamori M; Nakamura M; Katsuda M; Hayata K; Kato T; Kitadani J; Tabata H; Takeuchi A; Iwahashi M; Yamaue H
Anticancer Res; 2016 Feb; 36(2):829-34. PubMed ID: 26851048
[TBL] [Abstract][Full Text] [Related]
30. Prognosis of esophageal squamous cell carcinoma: analysis of clinicopathological and biological factors.
Wang LS; Chow KC; Chi KH; Liu CC; Li WY; Chiu JH; Huang MH
Am J Gastroenterol; 1999 Jul; 94(7):1933-40. PubMed ID: 10406262
[TBL] [Abstract][Full Text] [Related]
31. Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus.
Yamasaki M; Miyata H; Tanaka K; Shiraishi O; Motoori M; Peng YF; Yasuda T; Yano M; Shiozaki H; Mori M; Doki Y
Oncology; 2011; 80(5-6):307-13. PubMed ID: 21778771
[TBL] [Abstract][Full Text] [Related]
32. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone.
Ancona E; Ruol A; Santi S; Merigliano S; Sileni VC; Koussis H; Zaninotto G; Bonavina L; Peracchia A
Cancer; 2001 Jun; 91(11):2165-74. PubMed ID: 11391598
[TBL] [Abstract][Full Text] [Related]
33. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
Kauppi JT; Oksala N; Salo JA; Helin H; Karhumäki L; Kemppainen J; Sihvo EI; Räsänen JV
Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
[TBL] [Abstract][Full Text] [Related]
34. The nm23-H1 gene as a predictor of sensitivity to chemotherapeutic agents in oesophageal squamous cell carcinoma.
Iizuka N; Hirose K; Noma T; Hazama S; Tangoku A; Hayashi H; Abe T; Yamamoto K; Oka M
Br J Cancer; 1999 Oct; 81(3):469-75. PubMed ID: 10507772
[TBL] [Abstract][Full Text] [Related]
35. Tumor/normal esophagus ratio in (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for response and prognosis stratification after neoadjuvant chemotherapy for esophageal squamous cell carcinoma.
Izumi D; Yoshida N; Watanabe M; Shiraishi S; Ishimoto T; Kosumi K; Tokunaga R; Taki K; Higashi T; Harada K; Miyata T; Ida S; Imamura Y; Iwagami S; Baba Y; Sakamoto Y; Miyamoto Y; Yamashita Y; Baba H
J Gastroenterol; 2016 Aug; 51(8):788-95. PubMed ID: 26671045
[TBL] [Abstract][Full Text] [Related]
36. Reduced MLH1 expression after chemotherapy is an indicator for poor prognosis in esophageal cancers.
Kishi K; Doki Y; Yano M; Yasuda T; Fujiwara Y; Takiguchi S; Kim S; Higuchi I; Monden M
Clin Cancer Res; 2003 Oct; 9(12):4368-75. PubMed ID: 14555508
[TBL] [Abstract][Full Text] [Related]
37. Lack of survival advantage in patients with advanced, resectable squamous cell carcinoma of the oral cavity receiving induction chemotherapy with cisplatin (CDDP), docetaxel (TXT) and 5-fluorouracil (5FU).
Umeda M; Komatsubara H; Ojima Y; Minamikawa T; Shigeta T; Shibuya Y; Yokoo S; Komori T
Kobe J Med Sci; 2004; 50(5-6):189-96. PubMed ID: 16107776
[TBL] [Abstract][Full Text] [Related]
38. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial.
Bartlett JM; Munro A; Cameron DA; Thomas J; Prescott R; Twelves CJ
J Clin Oncol; 2008 Nov; 26(31):5027-35. PubMed ID: 18768436
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of combined docetaxel and nedaplatin chemotherapy for recurrent esophageal cancer compared with conventional chemotherapy using cisplatin and 5-fluorouracil: a retrospective study.
Fujita Y; Hiramatsu M; Kawai M; Sumiyoshi K; Nishimura H; Tanigawa N
Dis Esophagus; 2008; 21(6):496-501. PubMed ID: 18840134
[TBL] [Abstract][Full Text] [Related]
40. p53 genotype predicts response to chemotherapy in patients with squamous cell carcinoma of the esophagus.
Yamasaki M; Miyata H; Fujiwara Y; Takiguchi S; Nakajima K; Nishida T; Yasuda T; Matsuyama J; Mori M; Doki Y
Ann Surg Oncol; 2010 Feb; 17(2):634-42. PubMed ID: 19941080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
